Literature DB >> 19074874

Altered detoxification status and increased resistance to oxidative stress by K-ras transformation.

Christian V Recktenwald1, Roland Kellner, Rudolf Lichtenfels, Barbara Seliger.   

Abstract

Mutated K-ras is frequently found in human malignancies and plays a key role in many signal transduction processes resulting in an altered gene and/or protein expression pattern. Proteins controlled by a constitutive activated mitogen-activated protein kinase pathway are primarily related to alterations in the mitochondrial and nuclear compartments. Therefore, different K-Ras mutants and respective control cells were subjected to two-dimensional gel electrophoresis using basic pH gradients. This approach led to the identification of differentially expressed proteins, such as members of the heterogeneous ribonucleoprotein family, and enzymes involved in cellular detoxification as well as in oxidative stress. Increased expression of these enzymes was paralleled by an elevated tolerance of K-ras mutants against the cytotoxic potential of hydrogen peroxide and formaldehyde as well as an altered redox status based on enhanced intracellular glutathione (GSH) levels indicating an improved detoxification potential of defined K-ras transfectants, whereas down-regulation by RNA interference of candidate proteins reversed the tolerance against these compounds. This hypothesis is supported by an up-regulated expression of a key enzyme of the pentose phosphate pathway resulting in an increased production of NADPH required for anabolic processes as well as the rebuilding of oxidized GSH. Both the enhanced resistance against xenobiotic compounds as well as an altered oxidative pathway might confer growth advantages for tumor cells carrying dominant-positive K-ras mutations such as in lung or pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074874     DOI: 10.1158/0008-5472.CAN-08-0360

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Regulation of pancreatic cancer growth by superoxide.

Authors:  Juan Du; Elke S Nelson; Andrean L Simons; Kristen E Olney; Justin C Moser; Hannah E Schrock; Brett A Wagner; Garry R Buettner; Brian J Smith; Melissa L T Teoh; Ming-Sound Tsao; Joseph J Cullen
Journal:  Mol Carcinog       Date:  2012-03-05       Impact factor: 4.784

2.  Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Authors:  Haoqiang Ying; Alec C Kimmelman; Costas A Lyssiotis; Sujun Hua; Gerald C Chu; Eliot Fletcher-Sananikone; Jason W Locasale; Jaekyoung Son; Hailei Zhang; Jonathan L Coloff; Haiyan Yan; Wei Wang; Shujuan Chen; Andrea Viale; Hongwu Zheng; Ji-hye Paik; Carol Lim; Alexander R Guimaraes; Eric S Martin; Jeffery Chang; Aram F Hezel; Samuel R Perry; Jian Hu; Boyi Gan; Yonghong Xiao; John M Asara; Ralph Weissleder; Y Alan Wang; Lynda Chin; Lewis C Cantley; Ronald A DePinho
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

3.  Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.

Authors:  Barbara Seliger; Sven P Dressler; Chiara Massa; Christian V Recktenwald; Florian Altenberend; Juergen Bukur; Francesco M Marincola; Ena Wang; Stefan Stevanovic; Rudolf Lichtenfels
Journal:  Proteomics       Date:  2011-05-18       Impact factor: 3.984

4.  TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control.

Authors:  Jemma Gatliff; Daniel East; James Crosby; Rosella Abeti; Robert Harvey; William Craigen; Peter Parker; Michelangelo Campanella
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

5.  Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/SESN3/p21Cip1/WAF1 pathways.

Authors:  Maria Zamkova; Natalia Khromova; Boris P Kopnin; Pavel Kopnin
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

6.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Authors:  Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

Review 7.  Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.

Authors:  Abudureyimu Tuerhong; Jin Xu; Si Shi; Zhen Tan; Qingcai Meng; Jie Hua; Jiang Liu; Bo Zhang; Wei Wang; Xianjun Yu; Chen Liang
Journal:  Cell Mol Life Sci       Date:  2021-06-15       Impact factor: 9.261

8.  Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis.

Authors:  Rudolf Lichtenfels; Sven P Dressler; Monica Zobawa; Christian V Recktenwald; Angelika Ackermann; Derek Atkins; Michael Kersten; Andrea Hesse; Maria Puttkammer; Friedrich Lottspeich; Barbara Seliger
Journal:  Mol Cell Proteomics       Date:  2009-09-14       Impact factor: 5.911

9.  Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma.

Authors:  Kyle C McKenna; Kelly M Beatty; Richard A Bilonick; Lynn Schoenfield; Kira L Lathrop; Arun D Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-15       Impact factor: 4.799

10.  HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.

Authors:  Christian V Recktenwald; Sandra Leisz; André Steven; Kousaku Mimura; Anja Müller; Jens Wulfänger; Rolf Kiessling; Barbara Seliger
Journal:  J Biol Chem       Date:  2012-05-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.